{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:32:53Z","timestamp":1790652773429,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1245\/s10434-019-07236-8","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T22:08:57Z","timestamp":1551305337000},"page":"2127-2135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor"],"prefix":"10.1245","volume":"26","author":[{"given":"Meghan R.","family":"Flanagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Stempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Mangino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Pilewskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"issue":"9291","key":"7236_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389\u201399.","journal-title":"Lancet."},{"key":"7236_CR2","doi-asserted-by":"publisher","first-page":"747318","DOI":"10.1155\/2013\/747318","volume":"2013","author":"P Apostolou","year":"2013","unstructured":"Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:747318.","journal-title":"Biomed Res Int."},{"issue":"11","key":"7236_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333.","journal-title":"J Clin Oncol."},{"issue":"3","key":"7236_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-012-2318-8","volume":"136","author":"SB Coopey","year":"2012","unstructured":"Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627\u201333.","journal-title":"Breast Cancer Res Treat."},{"issue":"19","key":"7236_CR5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO.2006.09.0217","volume":"25","author":"AC Degnim","year":"2007","unstructured":"Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671\u20137.","journal-title":"J Clin Oncol."},{"issue":"1","key":"7236_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1(1):23\u201332.","journal-title":"JAMA Oncol."},{"issue":"1","key":"7236_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJMsr1407164","volume":"372","author":"LC Hartmann","year":"2015","unstructured":"Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast\u2013risk assessment and management options. N Engl J Med. 2015;372(1):78\u201389.","journal-title":"N Engl J Med."},{"issue":"5645","key":"7236_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643\u20136.","journal-title":"Science."},{"issue":"33","key":"7236_CR9","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","volume":"33","author":"TA King","year":"2015","unstructured":"King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945\u201352.","journal-title":"J Clin Oncol."},{"issue":"23","key":"7236_CR10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA."},{"issue":"21","key":"7236_CR11","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","volume":"32","author":"CS Moskowitz","year":"2014","unstructured":"Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217-23.","journal-title":"J Clin Oncol."},{"issue":"9","key":"7236_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","volume":"13","author":"N Tung","year":"2016","unstructured":"Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13(9):581\u20138.","journal-title":"Nat Rev Clin Oncol."},{"key":"7236_CR13","doi-asserted-by":"crossref","unstructured":"van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258\u201364.","DOI":"10.1038\/ajg.2009.725"},{"issue":"9880","key":"7236_CR14","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827\u201334.","journal-title":"Lancet."},{"key":"7236_CR15","unstructured":"Bevers TB, Armstrong DK, Arun B, Carlson RW. Breast cancer risk reduction. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology 2016;1.2017."},{"issue":"23","key":"7236_CR16","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","volume":"31","author":"K Visvanathan","year":"2013","unstructured":"Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942-62.","journal-title":"J Clin Oncol."},{"key":"7236_CR17","doi-asserted-by":"crossref","unstructured":"Moyer VA. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698\u2013708.","DOI":"10.7326\/0003-4819-159-10-201311190-00717"},{"issue":"24","key":"7236_CR18","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","volume":"22","author":"SL Bober","year":"2004","unstructured":"Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22(24):4951\u20137.","journal-title":"J Clin Oncol."},{"issue":"5","key":"7236_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1158\/1055-9965.EPI-06-0910","volume":"16","author":"VK Goldenberg","year":"2007","unstructured":"Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, et al. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007;16(5):1032\u20134.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"6","key":"7236_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clbc.2017.04.005","volume":"17","author":"DJ Hermel","year":"2017","unstructured":"Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, et al. Multi-institutional evaluation of women at high risk of developing breast cancer. Clin Breast Cancer. 2017;17(6):427\u201332.","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"7236_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/tbj.12418","volume":"21","author":"LL Reimers","year":"2015","unstructured":"Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, et al. Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast J. 2015;21(4):377\u201386.","journal-title":"Breast J."},{"issue":"4","key":"7236_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575\u201390.","journal-title":"Ann Oncol."},{"issue":"9","key":"7236_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/cncr.20205","volume":"100","author":"J Tchou","year":"2004","unstructured":"Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100(9):1800\u20136.","journal-title":"Cancer."},{"issue":"8","key":"7236_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1940-6207.CAPR-17-0100","volume":"10","author":"MS Trivedi","year":"2017","unstructured":"Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ. Cancer Prev Res (Phila). 2017;10(8):434\u201341.","journal-title":"Cancer Prev Res (Phila)."},{"issue":"7","key":"7236_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111\u201330.","journal-title":"Stat Med."},{"issue":"2","key":"7236_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125\u201337.","journal-title":"N Engl J Med."},{"issue":"23","key":"7236_CR27","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189\u201397.","journal-title":"JAMA."},{"issue":"18","key":"7236_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371\u201388.","journal-title":"J Natl Cancer Inst."},{"issue":"25","key":"7236_CR29","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381\u201391.","journal-title":"N Engl J Med."},{"issue":"23","key":"7236_CR30","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751\u201361.","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"7236_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djk050","volume":"99","author":"TJ Powles","year":"2007","unstructured":"Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283\u201390.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"7236_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/SLA.0000000000002045","volume":"267","author":"H Rivas","year":"2018","unstructured":"Rivas H, Robles I, Riquelme F, Vivanco M, Jimenez J, Marinkovic B,et al. Magnetic Surgery: Results From First Prospective Clinical Trial in 50 Patients. Ann Surg. 2018;267(1):88\u201393.","journal-title":"Ann Surg."},{"issue":"9122","key":"7236_CR33","first-page":"93","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352(9122):93\u20137.","journal-title":"Italian Tamoxifen Prevention Study. Lancet."},{"issue":"23","key":"7236_CR34","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727\u201341.","journal-title":"JAMA."},{"issue":"18","key":"7236_CR35","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","volume":"28","author":"ME Ropka","year":"2010","unstructured":"Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090\u20135.","journal-title":"J Clin Oncol."},{"issue":"7","key":"7236_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","volume":"8","author":"ER Port","year":"2001","unstructured":"Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8(7):580\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"7236_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1370\/afm.284","volume":"3","author":"R Taylor","year":"2005","unstructured":"Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3(3):242\u20137.","journal-title":"Ann Fam Med."},{"issue":"3","key":"7236_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","volume":"119","author":"A Fagerlin","year":"2010","unstructured":"Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, et al. Women\u2019s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119(3):613\u201320.","journal-title":"Breast Cancer Res Treat."},{"issue":"5 Pt 1","key":"7236_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1006\/pmed.1998.0349","volume":"27","author":"AY Kinney","year":"1998","unstructured":"Kinney AY, Richards C, Vernon SW, Vogel VG. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev Med. 1998;27(5 Pt 1):713\u20139.","journal-title":"Prev Med."},{"issue":"18","key":"7236_CR40","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251\u20136.","journal-title":"JAMA."},{"key":"7236_CR41","doi-asserted-by":"crossref","unstructured":"Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356(9245):1876\u201381.","DOI":"10.1016\/S0140-6736(00)03258-X"},{"issue":"7","key":"7236_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/bjc.2014.109","volume":"110","author":"LS Donnelly","year":"2014","unstructured":"Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer. 2014;110(7):1681\u20137.","journal-title":"Br J Cancer."},{"key":"7236_CR43","first-page":"624","volume":"52","author":"R Heisey","year":"2006","unstructured":"Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N. Women\u2019s views on chemoprevention of breast cancer: qualitative study. Can Fam Physician. 2006;52:624\u20135.","journal-title":"Can Fam Physician."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07236-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07236-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07236-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T19:16:05Z","timestamp":1582744565000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07236-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["7236"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07236-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"25 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Meghan R. Flanagan, Emily C. Zabor, Michelle Stempel, Debra A. Mangino, and Melissa L. Pilewskie have no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The preparation of this manuscript was funded in part by NIH\/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center. This study was presented in podium format at the 71st Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, USA, 21\u201324 March 2018. Dr. Monica Morrow has received honoraria from Roche and Genomic Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}